Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02794883
Recruitment Status : Active, not recruiting
First Posted : June 9, 2016
Last Update Posted : April 5, 2019
Sponsor:
Collaborators:
AstraZeneca
MedImmune LLC
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Northwestern University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2019
  Estimated Study Completion Date : June 2020